A synergistic, locally acting oral suspension combining the mucosal protective and ulcer-healing properties of sucralfate with the rapid topical anesthetic effect of oxetacaine. It is a first-line therapy for symptomatic relief and treatment of acid-peptic disorders in the Indian population, where dietary and lifestyle factors contribute to a high prevalence of gastritis and GERD.
Adult: 5 ml (one teaspoonful) four times a day: on an empty stomach (1 hour before meals) and at bedtime. For GERD: 10 ml (two teaspoonfuls) at bedtime may be used.
Note: SHAKE THE BOTTLE WELL BEFORE USE. Take on an empty stomach, at least 1 hour before meals and at bedtime. Do not dilute. Swallow the suspension undiluted. Do not take any other oral medication within 2 hours of taking this suspension, as it can bind to and reduce their absorption.
Sucralfate polymerizes in the acidic gastric environment (pH <4) to form a viscous, adhesive gel-like substance that binds selectively to ulcerated or eroded mucosa, creating a physical barrier against acid, pepsin, and bile salts. Oxetacaine provides immediate, surface-level anesthesia of the gastric and esophageal mucosa by blocking voltage-gated sodium channels, inhibiting nerve impulse conduction and providing rapid symptomatic pain relief.
Pregnancy: Category B (US FDA). Animal studies show no risk, but no adequate human studies. Sucralfate is minimally absorbed, making it a preferred non-systemic option for GERD/gastritis in pregnancy after antacids. Use only if potential benefit justifies potential risk, especially in 1st trimester.
Driving: Oxetacaine may rarely cause dizziness. Patients should not drive or operate machinery if they experience dizziness after taking the medication.
| Ciprofloxacin / Levofloxacin / Tetracycline | Sucralfate drastically reduces absorption of these antibiotics by chelation. Can lead to therapeutic failure. | Major |
| Digoxin, Levothyroxine, Warfarin | Sucralfate reduces absorption, decreasing efficacy. Monitor drug levels/effects. | Major |
| Phenytoin | Reduced phenytoin absorption and serum levels. | Moderate |
| Ketoconazole | Reduced ketoconazole absorption due to increased gastric pH from sucralfate's buffer effect. | Moderate |
| Antacids | Concurrent use may interfere with sucralfate's polymerization and binding to ulcers. | Moderate |
| Other Local Anesthetics | Additive systemic toxicity risk if oxetacaine is absorbed. | Minor |
Same composition (Sucralfate (500mg/5ml) + Oxetacaine (10mg/5ml)), different brands: